<DOC>
	<DOC>NCT02552160</DOC>
	<brief_summary>Prospective, multi-centre, non-interventional study to collect findings about the effects of LABA/LAMA (Long Acting Beta2-Agonists / Long Acting Muscarinic Antagonists) combination preparations on COPD (Chronic obstructive pulmonary disease) symptoms and quality of life under real conditions and to find out what types of patients are selected for this therapy by physicians.</brief_summary>
	<brief_title>DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy</brief_title>
	<detailed_description>Retrospective aspect of documentation: For patients who have already been changed over to a fixed-dose combination, lung function parameters and CAT (COPD Assessment Test™) score from the time prior to the changeover will be documented.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Female/male of at least 40 years of age Patient diagnosed with COPD Patient was changed over within the last 3 months to a fixeddose combination (FDC) (Aclidinium/Formeterol, Glycopyrronium/Indacaterol or Umeclidinium/Vilanterol), or there is already the intent to change the patient over to a fixeddose combination (Aclidinium/Formeterol, Glycopyrronium/Indacaterol or Umeclidinium/Vilanterol). Lung function parameters and CAT score from the time prior to the changeover to an FDC are on record (within the last 6 months in the case of patients who have already been changed over) or are determined at the 1st visit (in the case of patients who have not yet been changed over but for whom such a changeover is intended). Signed declaration of consent The prescribing information for the fixeddose combinations (Duaklir® Genuair®, Ulibtro® Breezhaler® or Anoro®) list contraindications for the patient. Patient is pregnant, plans to become pregnant, or is nursing during the therapy period. Patient suffers from hypersensitivity to one of the active ingredients of the fixeddose combinations. Patient is participating in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Fixed-dose Combination</keyword>
	<keyword>LAMA/LABA (Long Acting Beta2-Agonists / Long Acting Muscarinic Antagonists)</keyword>
	<keyword>Inhaler</keyword>
	<keyword>Aclidinium/Formoterol</keyword>
	<keyword>Glycopyrronium/Indacaterol</keyword>
	<keyword>Umeclidinium/Vilanterol</keyword>
</DOC>